Clinical Parkinsonism & Related Disorders is a prominent open-access journal published by Elsevier, focused on advancing the understanding and treatment of Parkinson's disease and related neurological conditions. Since its inception in 2019, this journal has aimed to provide a platform for high-quality research, review articles, and clinical studies dedicated to elucidating the complexities of Parkinsonism and its comorbidities. With an E-ISSN of 2590-1125, it has swiftly established its role in the field of clinical neurology, currently ranked in the Q3 quartile for clinical neurology and Q4 for cellular and molecular neuroscience. While its Scopus rankings reflect a competitive landscape, occupying the 241st position in clinical neurology and the 83rd in neuroscience, the journal remains committed to fostering scholarly dialogue and supporting innovative research. Researchers, clinicians, and students will find valuable insights within its pages, contributing to ongoing discourse and the pursuit of effective therapeutic strategies. Access to all articles has been made available since 2019, emphasizing the journal's mission to disseminate knowledge widely and enhance accessibility in the scientific community.

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

COMPREHENSIVE PSYCHIATRY is a leading peer-reviewed journal dedicated to advancing the field of psychiatry and mental health, published by W B SAUNDERS CO-ELSEVIER INC. With its Q1 designation in both Clinical Psychology and Psychiatry and Mental Health, this journal ranks impressively, holding the 9th position out of 311 in Clinical Psychology and the 27th position out of 567 in Psychiatry and Mental Health according to Scopus metrics. Since transitioning to Open Access in 2019, COMPREHENSIVE PSYCHIATRY has significantly increased its accessibility, enabling a broader audience of researchers, mental health professionals, and students to engage with cutting-edge research and clinical practices. The journal's scope encompasses a wide array of topics, including but not limited to evidence-based interventions, psychological evaluations, and the latest empirical studies in the field. As we continue to navigate the complexities of mental health in contemporary society, this journal serves as a vital resource for disseminating impactful findings and fostering collaborative discourse among scholars and practitioners globally.

Cognitive and Behavioral Neurology is a prominent peer-reviewed journal dedicated to advancing the understanding of cognitive and behavioral aspects of neurological disorders. Published by Lippincott Williams & Wilkins, this journal has established itself as a vital resource for researchers, clinicians, and students in the fields of cognitive neuroscience, neuropsychology, and psychiatry. With an ISSN of 1543-3633 and an E-ISSN of 1543-3641, it offers a robust platform for the dissemination of high-quality research, as evidenced by its positioning in the Q3 quartiles across various categories, including Cognitive Neuroscience and Psychiatry. The journal, which has been actively publishing since 2003, encourages innovative studies that explore the intersection of cognition and behavior in neurological contexts. As a vital contributor to the academic dialogue on these topics, it provides an essential archive of findings and discussions that inform clinical practice and educational approaches, reflecting its commitment to improving patient outcomes and enhancing neurological science.

Journal of Alzheimer's Disease Reports, published by IOS PRESS, is an essential open-access platform dedicated to advancing research in the fields of clinical psychology, geriatrics, gerontology, neuroscience, and psychiatry. Since its inception in 2017, this journal has rapidly gained recognition, achieving a commendable status reflected in its 2023 category quartiles, notably ranking Q2 in Clinical Psychology and Psychiatry and Mental Health. With a sustained commitment to disseminating high-quality research and facilitating collaboration among scientists, the journal offers insights into the critical aspects of Alzheimer's disease and related cognitive disorders. Given its positions in the Scopus ranks, it serves as a crucial resource for academics and practitioners alike, empowering them to contribute effectively to the ongoing discourse in cognitive health. The journal embraces open access, ensuring that all research findings are freely available to the global community, thereby enhancing visibility and engagement. With a focus on fostering innovation and knowledge transfer, Journal of Alzheimer's Disease Reports is poised to make an enduring impact in the field of dementia research.

The Journal of Attention Disorders is a premier peer-reviewed publication dedicated to advancing the understanding and treatment of attention-related disorders. Published by SAGE Publications Inc, this esteemed journal has become a vital resource in the fields of Clinical Psychology and Developmental and Educational Psychology, consistently ranking in the Q1 quartile for both categories as of 2023. With a significant impact factor and a commendable Scopus rank—#37 in Developmental and Educational Psychology and #34 in Clinical Psychology—this journal fosters innovative research and evidence-based practices that contribute to the mental health field. Since its inception in 1996, the Journal of Attention Disorders has provided a platform for the latest findings and discussions, supporting researchers, practitioners, and students alike. While the journal remains non-open access, it ensures rigorous dissemination of crucial information, solidifying its importance in shaping future research and best practices concerning attention disorders.

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

PSYCHIATRIC GENETICS, published by LIPPINCOTT WILLIAMS & WILKINS, is a pivotal journal dedicated to the interdisciplinary study of genetic factors in psychiatric disorders, bridging the fields of genetics, psychiatry, and neuroscience. With a commitment to advancing research from its inception in 1990 and continuing through 2024, the journal provides a platform for innovative studies and findings that explore the genetic underpinnings of mental health. Although not currently an Open Access publication, it reaches a wide audience concerned with the complex interplay between genetics and psychiatric conditions, contributing to its Q3 and Q2 quartile rankings across multiple relevant categories in 2023. The importance of this journal cannot be understated; it serves as a crucial resource for researchers, clinicians, and students eager to uncover insights that could lead to more effective interventions and treatments in the realm of mental health.

The JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, published by AMER PSYCHIATRIC PUBLISHING, INC, stands as a pivotal resource in the interdisciplinary fields of psychiatry, neurology, and mental health. With a history spanning from 1989 to 2024, this esteemed journal, identified by the ISSN 0895-0172 and E-ISSN 1545-7222, provides a platform for cutting-edge research and clinical insights into neuropsychiatric disorders. As of 2023, the journal is recognized in Q2 quartiles for Medicine (miscellaneous), Neurology (clinical), and Psychiatry and Mental Health, showcasing its significant impact within these domains, as evidenced by its Scopus rankings placing it in the 67th and 65th percentiles respectively. The journal emphasizes the importance of advancing knowledge through empirical studies, case reports, and reviews, making it an invaluable asset for researchers, clinicians, and students dedicated to understanding the complexities of the human brain and its psychological manifestations. Although the journal does not currently offer open access, it remains essential for those seeking to stay at the forefront of neuropsychiatric advancements.

Parkinson's Disease is a prestigious open access journal dedicated to advancing the field of neurology with a special emphasis on Parkinson's disease and related movement disorders. Published by Hindawi Ltd, the journal has established itself as a vital resource since its inception in 2008, transitioning to an open access model in 2010. Featuring the ISSN 2090-8083 and E-ISSN 2042-0080, it has rapidly gained traction in the academic community, currently ranked Q2 in clinical neurology and psychiatry in the 2023 category quartiles, highlighting its significance and quality within the field. With Scopus rankings placing it in the top percentiles for neuroscience and psychiatry, it provides researchers, healthcare professionals, and students with cutting-edge research, reviews, and clinical studies. Situated in London, England, this journal encourages submissions that contribute to the understanding and management of Parkinson's disease, showcasing the latest findings and fostering collaboration among researchers worldwide.